Cantor Fitzgerald Upgrades Cubist Pharmaceuticals (CBST) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steadies as US fuel demand concerns face Middle East supply risks
- Dollar sags after US GDP and inflation surprise, except against yen
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Cubist Pharmaceuticals, Inc. (CBST) Reports In-Line Q4 EPS
January 23, 2013 4:01 PM ESTCubist Pharmaceuticals, Inc. (NASDAQ: CBST) reported Q4 EPS of $0.48, in-line with the analyst estimate of $0.48. Revenue for the quarter came in at $245.9 million versus the consensus estimate of $246.42 million.
For earnings history and earnings-related data on Cubist Pharmaceuticals, Inc. (CBST) click here.... More
